Connection
Patrick Johnston to Cost-Benefit Analysis
This is a "connection" page, showing publications Patrick Johnston has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.148 |
|
|
|
-
Perales MA, Kuruvilla J, Snider JT, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel AR, Johnston PB. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial. Transplant Cell Ther. 2022 11; 28(11):750.e1-750.e6.
Score: 0.148